Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin. METHODS: Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367944/
https://www.ncbi.nlm.nih.gov/pubmed/34040174
http://dx.doi.org/10.1038/s41416-021-01406-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367944/
https://www.ncbi.nlm.nih.gov/pubmed/34040174
http://dx.doi.org/10.1038/s41416-021-01406-w

Ejemplares similares